The IPO pricing at the high end of the $16-$18 range signals strong investor demand, but the stock will likely experience post-IPO volatility. Monitor upcoming phase 2a combination trial (OD-001 + vedolizumab) and phase 2b monotherapy trial results expected in 2H2027—these are critical value inflection points. The concurrent private placement by an existing affiliate adds credibility but also indicates insider support.
Executive Summary
Odyssey Therapeutics priced its IPO at $18.00 per share, raising $279.0 million (15.5M shares) plus a concurrent $25.0 million private placement. The clinical-stage autoimmune company, which reported a net loss of $148.6M in 2025 and has a going concern qualification, will use proceeds to advance its lead programs OD-001 (RIPK2 inhibitor in phase 2a for UC) and OD-002 (SLC15A4 inhibitor) into mid-2028. The IPO was priced at the top of the revised range, reflecting strong demand despite the company's pre-revenue status and substantial accumulated deficit.
Key Financial Metrics
Key Facts
- IPO of 15,500,000 shares priced at $18.00/share, gross proceeds $279,000,000
- Concurrent private placement of 1,388,889 shares to TPG Orazio II for $25.0 million at the IPO price
- Net proceeds from IPO estimated at $255.4M; from private placement $23.3M
- Pro forma shares outstanding after offering and private placement: 47,174,156
- Company had $175.7M in preliminary cash as of March 31, 2026
- Net loss of $148.6M in 2025; accumulated deficit of $568.1M as of Dec 31, 2025
- Management has expressed substantial doubt about ability to continue as going concern
- Underwriters: J.P. Morgan, TD Cowen, Cantor, Wedbush PacGrow, Oppenheimer & Co.
- Lock-up agreements for 180 days with directors, officers, and substantially all security holders
Financial Impact
Net proceeds of approximately $278.7 million from the IPO and concurrent private placement, extending runway into second half of 2028
Risk Factors
- Pre-revenue with no approved products and history of significant operating losses
- Going concern qualified by management; substantial doubt about ability to continue
- Clinical-stage pipeline with only one asset in phase 2a; high risk of failure in later trials
- Dilution of 32.9% for existing shareholders from IPO and private placement
- Need for substantial additional capital beyond current runway to complete development
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B4 Filing (Primary) | 0001193125-26-214819 |
| Document: 0001193125-26-214819-index-headers.html | 0001193125-26-214819 |
| Document: 0001193125-26-214819-index.html | 0001193125-26-214819 |
| Document: 0001193125-26-214819.txt | 0001193125-26-214819 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | 8-K | $18.99 $19.00 | ▲ +0.05% | ▼ −0.47% | $19.26 (+1.45%) |
Aug 4, 2026 11w ago | 8-K | $19.96 $20.89 | ▲ +4.66% | ▲ +4.86% | $19.26 (−3.48%) |
Jun 17, 2026 18w ago | 8-K | $19.07 $18.72 | ▼ −1.84% | ▼ −1.52% | $19.26 (+1.02%) |
May 11, 2026 24w ago | Insider Cluster | $17.45 $17.90 | ▲ +2.58% | ▲ +2.72% | $19.26 (+10.40%) |
May 8, 2026 24w ago | 424B4 | $17.45 $17.90 | ▲ +2.58% | ▲ +2.72% | $19.26 (+10.40%) |
May 8, 2026 24w ago | EFFECT | $16.42 $17.45 | ▲ +6.27% | ▲ +6.04% | $19.26 (+17.33%) |
May 7, 2026 24w ago | 3 | $16.42 $17.45 | ▲ +6.27% | ▲ +6.04% | $19.26 (+17.33%) |
May 7, 2026 24w ago | 3 | $16.42 $17.45 | ▲ +6.27% | ▲ +6.04% | $19.26 (+17.33%) |
May 7, 2026 24w ago | 3 | $16.42 $17.45 | ▲ +6.27% | ▲ +6.04% | $19.26 (+17.33%) |
May 7, 2026 24w ago | 3 | $16.42 $17.45 | ▲ +6.27% | ▲ +6.04% | $19.26 (+17.33%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers